Meta-research metrics matter: letter regarding article “indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease”

Here we discuss the report by Claassen and colleagues describing an indirect treatment comparison between tetrabenazine and deutetrabenazine for chorea in Huntington’s disease using individual patient data. We note the potential for discrepancies in apparently statistically significant findings, due...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodrigues, Filipe B., Duarte, Gonçalo S., Costa, João, Ferreira, Joaquim J., Wild, Edward J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5698972/
https://www.ncbi.nlm.nih.gov/pubmed/29201386
http://dx.doi.org/10.1186/s40734-017-0067-x
_version_ 1783280863122817024
author Rodrigues, Filipe B.
Duarte, Gonçalo S.
Costa, João
Ferreira, Joaquim J.
Wild, Edward J.
author_facet Rodrigues, Filipe B.
Duarte, Gonçalo S.
Costa, João
Ferreira, Joaquim J.
Wild, Edward J.
author_sort Rodrigues, Filipe B.
collection PubMed
description Here we discuss the report by Claassen and colleagues describing an indirect treatment comparison between tetrabenazine and deutetrabenazine for chorea in Huntington’s disease using individual patient data. We note the potential for discrepancies in apparently statistically significant findings, due to the rank reversal phenomenon. We provide some cautionary observations and suggestions concerning the limitations of indirect comparisons and the low likelihood that good quality evidence will become available to guide clinical decision comparing these two agents.
format Online
Article
Text
id pubmed-5698972
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-56989722017-12-01 Meta-research metrics matter: letter regarding article “indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease” Rodrigues, Filipe B. Duarte, Gonçalo S. Costa, João Ferreira, Joaquim J. Wild, Edward J. J Clin Mov Disord Letter to the Editor Here we discuss the report by Claassen and colleagues describing an indirect treatment comparison between tetrabenazine and deutetrabenazine for chorea in Huntington’s disease using individual patient data. We note the potential for discrepancies in apparently statistically significant findings, due to the rank reversal phenomenon. We provide some cautionary observations and suggestions concerning the limitations of indirect comparisons and the low likelihood that good quality evidence will become available to guide clinical decision comparing these two agents. BioMed Central 2017-11-22 /pmc/articles/PMC5698972/ /pubmed/29201386 http://dx.doi.org/10.1186/s40734-017-0067-x Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Letter to the Editor
Rodrigues, Filipe B.
Duarte, Gonçalo S.
Costa, João
Ferreira, Joaquim J.
Wild, Edward J.
Meta-research metrics matter: letter regarding article “indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease”
title Meta-research metrics matter: letter regarding article “indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease”
title_full Meta-research metrics matter: letter regarding article “indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease”
title_fullStr Meta-research metrics matter: letter regarding article “indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease”
title_full_unstemmed Meta-research metrics matter: letter regarding article “indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease”
title_short Meta-research metrics matter: letter regarding article “indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease”
title_sort meta-research metrics matter: letter regarding article “indirect tolerability comparison of deutetrabenazine and tetrabenazine for huntington disease”
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5698972/
https://www.ncbi.nlm.nih.gov/pubmed/29201386
http://dx.doi.org/10.1186/s40734-017-0067-x
work_keys_str_mv AT rodriguesfilipeb metaresearchmetricsmatterletterregardingarticleindirecttolerabilitycomparisonofdeutetrabenazineandtetrabenazineforhuntingtondisease
AT duartegoncalos metaresearchmetricsmatterletterregardingarticleindirecttolerabilitycomparisonofdeutetrabenazineandtetrabenazineforhuntingtondisease
AT costajoao metaresearchmetricsmatterletterregardingarticleindirecttolerabilitycomparisonofdeutetrabenazineandtetrabenazineforhuntingtondisease
AT ferreirajoaquimj metaresearchmetricsmatterletterregardingarticleindirecttolerabilitycomparisonofdeutetrabenazineandtetrabenazineforhuntingtondisease
AT wildedwardj metaresearchmetricsmatterletterregardingarticleindirecttolerabilitycomparisonofdeutetrabenazineandtetrabenazineforhuntingtondisease

Ejemplares similares